精神科医 : 臨床および治療ジャーナル

抽象的な

In the Treatment of Schizophrenia and Depression, New Atypical Antipsychotics

Julianne Pelegrino

Depression and schizophrenia are distinct mental illnesses.Due to the intricate pathomechanisms of the diseases, patients may respond differently to medication.Although there are numerous psychotropic medications on the market, achieving the best therapeutic effect can be difficult.New atypical antipsychotic medications may be effective against the affective symptoms of depression as well as the negative and cognitive symptoms of schizophrenia based on their strong correlation with clinical observations.Aripiprazole, cariprazine, lurasidone, asenapine, brexpiprazole, lumateperone, and pimavanserin—new antipsychotics of the second and third generations—are used to treat depression and schizophrenia. The purpose of this review is to provide background information as well as evidence for these medications.We have initially briefly discussed the major neurobiological causes of schizophrenia and depression. The benefits, drawbacks, and dangers of continuing pharmacotherapy for depression and schizophrenia are then briefly discussed.The primary focus of this review was on the current therapeutic potential of new atypical antipsychotic medications for the treatment of psychotic and affective disorders.